Skip Nav Destination
Issues
1 June 2007
-
Cover Image
Cover Image
The effects of curcumin on NF-κB (top row), phospho-STAT3 (middle row), and COX-2 (bottom row) expression were examined in an orthotopic mouse model of ovarian carcinoma. Compared with controls (left column), treatment with oral curcumin (500 mg/kg) decreased expression of NF-κB (p65), phospho-STAT3, and COX-2 as early as 24 hours after the last dose (middle column). Expression of these three factors returned to baseline levels by 72 hours after treatment (right column). The potent inhibition of these critical tumorigenic and angiogenic factors evidenced here support the development of curcumin-based therapeutic strategies for ovarian carcinoma. For further details, please see Lin et al. on page 3423 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Editorial
The Biology Behind
Molecular Pathways
Human Cancer Biology
Imaging, Diagnosis, Prognosis
Cytokeratin-18 Is a Useful Serum Biomarker for Early Determination of Response of Breast Carcinomas to Chemotherapy
Maria Hägg Olofsson; Takayuki Ueno; Yang Pan; Ren Xu; Feng Cai; Heiko van der Kuip; Thomas E. Muerdter; Maike Sonnenberg; Walter E. Aulitzky; Stephan Schwarz; Elina Andersson; Maria C. Shoshan; Aleksandra Mandic Havelka; Masakazu Toi; Stig Linder
Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series
Christine Desmedt; Fanny Piette; Sherene Loi; Yixin Wang; Françoise Lallemand; Benjamin Haibe-Kains; Giuseppe Viale; Mauro Delorenzi; Yi Zhang; Mahasti Saghatchian d'Assignies; Jonas Bergh; Rosette Lidereau; Paul Ellis; Adrian L. Harris; Jan G.M. Klijn; John A. Foekens; Fatima Cardoso; Martine J. Piccart; Marc Buyse; Christos Sotiriou; on behalf of the TRANSBIG Consortium
Distinction of Hereditary Nonpolyposis Colorectal Cancer and Sporadic Microsatellite-Unstable Colorectal Cancer through Quantification of MLH1 Methylation by Real-time PCR
Marcus Bettstetter; Stephan Dechant; Petra Ruemmele; Monika Grabowski; Gisela Keller; Elke Holinski-Feder; Arndt Hartmann; Ferdinand Hofstaedter; Wolfgang Dietmaier
Cancer Therapy: Clinical
A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen
Andrew M. Scott; Niall Tebbutt; Fook-Thean Lee; Tina Cavicchiolo; Zhanqi Liu; Sanjeev Gill; Aurora M.T. Poon; Wendie Hopkins; Fiona E. Smyth; Carmel Murone; Duncan MacGregor; Anthony T. Papenfuss; Bridget Chappell; Timothy H. Saunder; Martin W. Brechbiel; Ian D. Davis; Roger Murphy; Geoffrey Chong; Eric W. Hoffman; Lloyd J. Old
Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel
Alain C. Mita; Anthony J. Olszanski; Richard C. Walovitch; Raymond P. Perez; Kathleen MacKay; David P. Tuck; Cecilia Simmons; Susan Hammond; Monica M. Mita; Muralidhar Beeram; Anne J. Stone; Eric K. Rowinsky; Lionel D. Lewis
A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871
Lionel D. Lewis; Antonius A. Miller; Gary L. Rosner; Jonathan E. Dowell; Manuel Valdivieso; Mary V. Relling; Merrill J. Egorin; Robert R. Bies; Donna R. Hollis; Ellis G. Levine; Gregory A. Otterson; Frederick Millard; Mark J. Ratain; for the Cancer and Leukemia Group B
Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer
Kim Margolin; Michael B. Atkins; Janice P. Dutcher; Marc S. Ernstoff; John W. Smith, II; Joseph I. Clark; Joseph Baar; Jeffrey Sosman; Jeffrey Weber; Chetan Lathia; Janice Brunetti; Frank Cihon; Brian Schwartz
Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248
Steven P. Treon; Zachary R. Hunter; Jeffrey Matous; Robin M. Joyce; Brian Mannion; Ranjana Advani; David Cook; Joseph Songer; John Hill; Bruce R. Kaden; David Sharon; Ronald Steiss; Xavier Leleu; Andrew R. Branagan; Ashraf Badros
Cancer Therapy: Preclinical
Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2′-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications
Ester Fonsatti; Hugues J.M. Nicolay; Luca Sigalotti; Luana Calabrò; Laura Pezzani; Francesca Colizzi; Maresa Altomonte; Massimo Guidoboni; Francesco M. Marincola; Michele Maio
In vivo Therapeutic Synergism of Anti–Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas
Christel Larbouret; Bruno Robert; Isabelle Navarro-Teulon; Simon Thèzenas; Maha-Zohra Ladjemi; Sébastien Morisseau; Emmanuelle Campigna; Frédéric Bibeau; Jean-Pierre Mach; André Pèlegrin; David Azria
Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis
Ronald Koschny; Heidrun Holland; Jaromir Sykora; Tobias L. Haas; Martin R. Sprick; Tom M. Ganten; Wolfgang Krupp; Manfred Bauer; Peter Ahnert; Jürgen Meixensberger; Henning Walczak
Curcumin Inhibits Tumor Growth and Angiogenesis in Ovarian Carcinoma by Targeting the Nuclear Factor-κB Pathway
Yvonne G. Lin; Ajaikumar B. Kunnumakkara; Asha Nair; William M. Merritt; Liz Y. Han; Guillermo N. Armaiz-Pena; Aparna A. Kamat; Whitney A. Spannuth; David M. Gershenson; Susan K. Lutgendorf; Bharat B. Aggarwal; Anil K. Sood
Letters to the Editor
Correction
Advertisement